Alder Biopharmaceuticals, Inc. (ALDR) Promises to Relieve Migraine Misery with Leading Drug Candidate ALD403
A research report (http://nnw.fm/eAD2R) issued earlier this week by Aegis Capital Corp. shows that Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR) has lived up to its promise since 2004, when it received startup funding from the Army under the Small Business Technology Transfer (STTR) program. Since then the company has been working on the development of new production technologies for humanized antibodies. Now it is close to making the fruits of that research available for the treatment of migraine, inflammatory diseases and autoimmune diseases with its lead product candidate, ALD403. Results of ongoing clinical trials are quite promising. Trials of ALD403 go…







